Your browser doesn't support javascript.
May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
Adamowicz, Jan; Juszczak, Kajetan; Drewa, Tomasz.
  • Adamowicz J; Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Curie-Sklodowskiej 9, 85 094 Bydgoszcz, Poland.
  • Juszczak K; Reconstructive Urology Working Group, Young Academic Urologists, European Association of Urology, Poland.
  • Drewa T; Department of Urology, Collegium Medicum, Nicolaus Copernicus University, Curie-Sklodowskiej 9, 85 094 Bydgoszcz, Poland.
Med Hypotheses ; 140: 109751, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-102029
ABSTRACT
COVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females. Based on this observation, our proposed hypothesis is that 5-alpha-reductase inhibitors, that are commonly used for BPH treatment, may be one of the factors contributing to poorer prognosis in males.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / 5-alpha Reductase Inhibitors Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Animals / Humans / Male Language: English Journal: Med Hypotheses Year: 2020 Document Type: Article Affiliation country: J.mehy.2020.109751

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / 5-alpha Reductase Inhibitors Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Animals / Humans / Male Language: English Journal: Med Hypotheses Year: 2020 Document Type: Article Affiliation country: J.mehy.2020.109751